Adial Pharmaceuticals, Inc. (AZR) stock
AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
Adial Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Adial Pharmaceuticals's total assets was $29.09M at Jun 30, 2026. For fiscal 2025 it was $6.67M, up 32.3% from the year before. The highest annual figure on record is $7.68M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.67M | +32.3% |
| FY2024 | Dec 31, 2024 | $5.04M | +6.5% |
| FY2023 | Dec 31, 2023 | $4.74M | -17.4% |
| FY2022 | Dec 31, 2022 | $5.73M | -23.3% |
| FY2021 | Dec 31, 2021 | $7.47M | +36.1% |
| FY2020 | Dec 31, 2020 | $5.49M | -28.5% |
| FY2019 | Dec 31, 2019 | $7.68M | +63.4% |
| FY2018 | Dec 31, 2018 | $4.70M | +13503.0% |
| FY2017 | Dec 31, 2017 | $34.55K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.09M | +327.7% |
| Q1 FY2026 | Mar 31, 2026 | $5.23M | +51.5% |
| Q4 FY2025 | Dec 31, 2025 | $6.67M | +32.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.66M | -15.7% |
| Q2 FY2025 | Jun 30, 2025 | $6.80M | +37.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.45M | -48.4% |
| Q4 FY2024 | Dec 31, 2024 | $5.04M | +6.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.71M | +134.1% |
| Q2 FY2024 | Jun 30, 2024 | $4.95M | +31.0% |
| Q1 FY2024 | Mar 31, 2024 | $6.68M | +71.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.74M | -17.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.87M | -63.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.78M | -65.4% |
| Q1 FY2023 | Mar 31, 2023 | $3.90M | -72.1% |
| Q4 FY2022 | Dec 31, 2022 | $5.73M | -23.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.74M | -25.9% |
| Q2 FY2022 | Jun 30, 2022 | $10.92M | +35.5% |
| Q1 FY2022 | Mar 31, 2022 | $13.96M | +61.9% |
| Q4 FY2021 | Dec 31, 2021 | $7.47M | +36.1% |
| Q3 FY2021 | Sep 30, 2021 | $10.45M | +27.7% |
| Q2 FY2021 | Jun 30, 2021 | $8.06M | -14.9% |
| Q1 FY2021 | Mar 31, 2021 | $8.63M | +45.2% |
| Q4 FY2020 | Dec 31, 2020 | $5.49M | -28.5% |
| Q3 FY2020 | Sep 30, 2020 | $8.18M | -14.0% |
| Q2 FY2020 | Jun 30, 2020 | $9.47M | -11.3% |
| Q1 FY2020 | Mar 31, 2020 | $5.94M | -50.7% |
| Q4 FY2019 | Dec 31, 2019 | $7.68M | +63.4% |
| Q3 FY2019 | Sep 30, 2019 | $9.51M | +81.0% |
| Q2 FY2019 | Jun 30, 2019 | $10.69M | +5612.5% |
| Q1 FY2019 | Mar 31, 2019 | $12.06M | +34809.8% |
| Q4 FY2018 | Dec 31, 2018 | $4.70M | – |
| Q3 FY2018 | Sep 30, 2018 | $5.25M | – |
| Q2 FY2018 | Jun 30, 2018 | $187.09K | – |
| Q4 FY2017 | Dec 31, 2017 | $34.55K | – |